What it sells
AI-driven clinical trials.
Business model breakdown
Buyer: who owns the budget?
UnverifiedClinical development and operations heads at biopharma sponsors and CROs.
Trigger: what makes them buy now?
Slow, costly trials with many protocol amendments; competitive pressure to reach approval first.
Workflow: what inputs become what output?
Aika generates protocol, IB and ICF in minutes, simulates and checks feasibility, handles contracts/budgets, site activation, eligibility, regulatory and data in one operating system.
Economics: what it saves and how it charges
Enterprise platform; claims 60% cost reduction, 70% faster workflow, 50% fewer protocol amendments.
Distribution: how it reaches customers
Demo-led ('Book a demo', 'Access Aika'), partnerships and events.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-02-02 | Series A | €43.8M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.